OBJECTIVE： To investigate clinical efficacy and safety of Rosuvastatin calcium tablets combined with Qishen yiqi dripping pills in the treatment of chronic heart failure （CHF） and it effects on inflammatory level， oxidative stress injury and cardiac function of patients. METHODS： Ninety CHF patients in our hospital during Aug. 2014-Apr. 2016 were divided into observation group and control group according to random number table， with 45 cases in each group. Control group received routine anti-heart failure treatment as cardiac， diuretic， dilating vessel， and Qishen yiqi dripping pills orally 0.5 g， half an hour after meal， tid； observation group was additionally given Rosuvastatin calcium tablet orally 20 mg， at bedtime， qd， on the basis of control group. Cardiac function， serum inflammatory factor， BNP and oxidative stress levels were compared between 2 groups before and after treatment. Clinical efficacies and the occurrence of ADR were observed in 2 groups. RESULTS： Before treatment， there was no statistical significance in LVEF， LVESD， LVEDD， TNF-α， IL-6， BNP， SOD， MPO and MMP-9 levels between 2 groups （P＞0.05）. After treatment， LVEF of 2 groups were increased significantly， while LVEDD， LVESD， TNF-α and IL-6， BNP levels were decreased significantly； the above indexes of observation group was significantly better than those of  control group， with statistical significance （P＜0.05）. MPO and MMP-9 of observation group were significantly decreased， while SOD level was significantly increased and better than that of control group， with statistical significance （P＜0.05）， but there was no statistical significance in SOD and MPO， MMP-9 levels of control group before and after treatment （P＞0.05）. The clinical response rate of observation group was 97.8％， which was significantly higher than 82.2％ of control group， with statistical significance （P＜0.05）. There was no statistical significance in the incidence of ADR between 2 groups （P＞0.05）. CONCLUSIONS： Rosuvastatin calcium tablets combined with Qishen yiqi dripping pills show significant therapeutic efficacy for CHF， can effectively reduce inflammatory level， relieve oxidant stress injury， delay the process of ventricular remodeling， and improve cardiac function with good safety.